Dr. Birrer on Checkpoint Inhibitors for Endometrial Cancer | OncLive

Dr. Birrer on Checkpoint Inhibitors for Endometrial Cancer

June 20, 2017

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses checkpoint inhibitors for patients with endometrial cancer.

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses checkpoint inhibitors for patients with endometrial cancer.

Across all tumor types, there is a growing excitement around checkpoint inhibitors, which is the case in endometrial cancer as well, explains Birrer. There is a subset of patients with endometrial cancers that are microsatellite instability-high (MSI-H).

Recently, there was an approval for MSI-H tumors; however, there is still a study investigating what the response rate is for patients with endometrial cancer since the approval was based on very few patients, states Birrer.


x